An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer

Phipps A.I., Buchanan D., Makar K.W., Et al., KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers, Br J Cancer, 108, pp. 1757-1764, (2013)

Thibodeau S.N., Bren G., Schaid D., Microsatellite instability in cancer of the proximal colon, Science, 260, pp. 816-819, (1993)

Marra G., Boland C.R., Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives, J Natl Cancer Inst, 87, pp. 1114-1125, (1995)

Bronner C.E., Baker S.M., Morrison P.T., Et al., Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer, Nature, 368, pp. 258-261, (1994)

Cunningham J.M., Christensen E.R., Tester D.J., Et al., Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability, Cancer Res, 58, pp. 3455-3460, (1998)

Andreyev H.J., Norman A.R., Cunningham D., Et al., Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study, J Natl Cancer Inst, 90, pp. 675-684, (1998)

De Roock W., Claes B., Bernasconi D., Et al., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol, 11, pp. 753-762, (2010)

De Roock W., Jonker D.J., Di Nicolantonio F., Et al., Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab, JAMA, 304, pp. 1812-1820, (2010)

Gnanasampanthan G., Elsaleh H., McCaul K., Et al., Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes’ C colorectal cancer, J Pathol, 195, pp. 543-548, (2001)

Hutchins G., Southward K., Handley K., Et al., Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer, J Clin Oncol, 29, pp. 1261-1270, (2011)

Phipps A.I., Buchanan D., Makar K.W., Et al., KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers, Br J Cancer, 108, pp. 1757-1764, (2013)

Thibodeau S.N., Bren G., Schaid D., Microsatellite instability in cancer of the proximal colon, Science, 260, pp. 816-819, (1993)

Marra G., Boland C.R., Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives, J Natl Cancer Inst, 87, pp. 1114-1125, (1995)

Bronner C.E., Baker S.M., Morrison P.T., Et al., Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer, Nature, 368, pp. 258-261, (1994)

Cunningham J.M., Christensen E.R., Tester D.J., Et al., Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability, Cancer Res, 58, pp. 3455-3460, (1998)

Andreyev H.J., Norman A.R., Cunningham D., Et al., Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study, J Natl Cancer Inst, 90, pp. 675-684, (1998)

De Roock W., Claes B., Bernasconi D., Et al., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol, 11, pp. 753-762, (2010)

De Roock W., Jonker D.J., Di Nicolantonio F., Et al., Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab, JAMA, 304, pp. 1812-1820, (2010)

Gnanasampanthan G., Elsaleh H., McCaul K., Et al., Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes’ C colorectal cancer, J Pathol, 195, pp. 543-548, (2001)

Hutchins G., Southward K., Handley K., Et al., Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer, J Clin Oncol, 29, pp. 1261-1270, (2011)